In this study, we aimed at assessing if a 6-month administration of tofersen, a specific drug for the treatment of ALS associated with SOD1 gene mutations, could modify the distribution of the metalloid selenium in the CNS, and more specifically in CSF. Here, SOD1 is linked to amyotrophic lateral sclerosis.